Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
557
Views
5
CrossRef citations to date
0
Altmetric
Systematic review

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review

Anthony Yua School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United StatesView further author information
,
Eva Huanga School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United StatesView further author information
,
Momoka Abea School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United StatesView further author information
,
Kang Ana School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United StatesView further author information
,
Sun-Kyeong Parkb College of Pharmacy, The Catholic University of Korea, Bucheon, South KoreaView further author information
&
Chanhyun Parka School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United StatesCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1081-0950View further author information
ORCID Icon
Pages 381-393 | Received 07 Jan 2021, Accepted 04 Feb 2021, Published online: 22 Feb 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now

Articles from other publishers (4)

Lara Chayab, Natalia Konstantelos, Natasha B. Leighl, Mina Tadrous & William W. L. Wong. (2023) A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). PharmacoEconomics 41:8, pages 945-980.
Crossref
Lai-Jun Deng, Yang Dong, Mi-Mi Li & Chang-Gang Sun. (2023) Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report . World Journal of Clinical Cases 11:15, pages 3643-3650.
Crossref
Ting Zhou & Feng Xie. (2023) Sponsorship bias in oncology cost effectiveness analysis. Journal of Clinical Epidemiology 156, pages 22-29.
Crossref
Remziye Zaim, W. Ken Redekop & Carin A. Uyl-de Groot. (2023) Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment. Frontiers in Health Services 3.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.